gel-e quickly stops bleeds using an inert, self-assembling biopolymer... now cleared by the FDA for gel-e's vascular access bandage*

gel-e's technology is a revolutionary platform for developing advanced wound treatment and hemostatic materials. gel-e is designed to create rapid coagulation with biological safety, has ease-of-use, is highly durable, and has inherent anti-microbial properties. The primary advantage of our product line is the superior combination of rapid blood-material interaction resulting in robust barrier formation. gel-e products are engineered to be used across a broad spectrum of clinical settings, ranging from routine lacerations, nosebleeds, traumatic injuries, surgical bleeds, burns and even diabetic ulcers. All of these products are manufactured using a simple and scalable modified chitosan base material which is highly abundant in nature.

gel-e is made from a combination of safe ingredients. The first component is chitosan, which is the second-most abundant biopolymer on earth next to cellulose. Chitosan is a structural biomaterial found in shrimps, crabs, insects and mushrooms; it is unique as a natural material in that it is (a) mucoadhesive, (b) anti-microbial, (c) biocompatible, and (d) highly durable. This makes chitosan a superior starting ingredient for creating wound treatment products. We combine chitosan in a proprietary fashion with natural plant-based fatty acids to create hydrophobically-modified (hm) chitosan. hm-chitosan forms the gel-e matrix, which is able to rapidly self-assemble into robust physical seals designed to stop bleeding, completely independent of the body’s clotting cascade.

The inert, abundant, naturally harvested components that constitute gel-e's product line provide for highly scalable manufacturing. gel-e's technology platform is also extremely functional after a clot has formed through use of gel-e® Reverse, a simple innovative de-clotting agent designed specifically to reverse the strong bonds created by gel-e's product line.

Indicated for use, under the direction of a healthcare professional, in the management of bleeding wounds such as vascular access sites and percutaneous catheters or tubes. Not yet commercially available.